Ocular effects of treatment with various psoralen derivatives and ultraviolet-A (UVA) radiation in HRA/Skh hairless mice.
Hairless (HRA/Skh) mice were administered one of four dietary concentrations (50, 100, 625 or 1250 ppm) of 8-methoxypsoralen (8-MOP) or 5-methoxypsoralen (5-MOP), or molar equivalent concentrations of 5-methylisopsoralen (5-MIP) or 3-carbethoxypsoralen (3-CPS) by 'pulse feeding' technique, 3 days per week for 13 weeks. For the final 11 weeks psoralen derivative administration was followed by exposure to 0.2 or 48 J/cm2 of unfiltered ultraviolet-A (UVA) radiant energy from FR74T12PUVA lamps. At 0 and 13 weeks eyes were dilated with 0.2% atropine solution and were examined using a binocular indirect ophthalmoscope with a +20.0 D condensing lens. The lids, cornea, anterior chamber and the lens were evaluated for pathological changes. Ocular damage consisting of dense central corneal opacification was seen at significant levels in animals given 8-MOP or 5-MOP and exposed to UVA. In addition, opacities in the area of the posterior lens were seen in all experimental groups and appeared to be related to drug treatment, independent of light exposure, and therefore appeared not to be related to drug-light interaction. Some corneal and lenticular opacification was seen at non-significant levels in all experimental and control groups.
D000078223:5-Methoxypsoralen; D000818:Animals; D002386:Cataract / Q000139:chemically induced; D003318:Corneal Opacity / Q000139:chemically induced; D005123:Eye / Q000187:drug effects*; D011564:Furocoumarins / Q000009:adverse effects*; D008730:Methoxsalen / Q000009:adverse effects; D051379:Mice; D008812:Mice, Hairless; D011701:PUVA Therapy / Q000009:adverse effects*; D010781:Photography
D011564:Furocoumarins; D000078223:5-Methoxypsoralen; C023026:5-methylangelicin; C017104:3-carbethoxypsoralen; D008730:Methoxsalen